IP Library Patent Application 10990007
Patent Application
App. No. 10/990,007

Amide derivatives as C-KIT modulators

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/990,007
Abstract

The invention provides methods and compositions for treating conditions mediated by c-kit wherein derivatives of amide compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.

Claims (121)

1 . A method of modulating c-kit kinase, said method comprising administering an effective amount of a compound corresponding to Formula (IA):

wherein:

M is substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl;

N is a substituted or unsubstituted aryl, or substituted or unsubstituted hetroaryl; and

K is

Y is O or S;

each R k is independently H, halogen, substituted or unsubstituted alkyl, —OH, substituted or unsubstituted alkoxy, —OC(O)R 2 , —NO 2 , —N(R 2 ) 2 , —SR 2 , —C(O)R 2 , —C(O) 2 R 2 , —C(O)N(R 2 ) 2 , or —N(R 2 )C(O)R 2 ,

each R 2 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or wherein two R 2 groups are linked together by an optionally substituted alkylene; and

each n is independently 0, 1, 2, 3 or 4;

or an active metabolite, or a pharmaceutically acceptable prodrug, isomer, pharmaceutically acceptable salt or solvate thereof.

2 . The method of claim 1 , wherein said compound corresponds to Formula (IB):

wherein:

each Z is independently C, CR 3 , N, NR 3 , O, or S, provided that no more than two Z's are heteroatoms and wherein no two adjacent Z's are O or S, where R 3 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl; and

each R 1 is independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR c —OH, —OC(O)R c , —NO 2 , —N(R c ) 2 , —SR c , S(O) j R c where j is 1 or 2, —NR c C(O)R c , —C(O)N(R c ) 2 , —C(O) 2 R c , or —C(O)R c ; or two adjacent R 1 's, are taken together to form a substituted or unsubstituted aryl or heteroaryl,

each R c is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

3 . The method of claim 2 , wherein said compound corresponds to Formula (I):

wherein K is

each R k is independently H, halogen, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy.

4 . The method of claim 3 , wherein said compound corresponds to Formula (II):

5 . The method of claim 4 , wherein said compound corresponds to Formula (III):

wherein Z 1 is CR 3 or N; and Z 2 is O or S.

6 . The method of claim 5 , wherein said compound corresponds to Formula (IV):

wherein:

each R 1 is independently H, halogen, substituted or unsubstituted alkyl, —O(substituted or unsubstituted alkyl), —O(substituted or unsubstituted alkenyl), —NR c C(O)O(substituted or unsubstituted alkyl), —NR c C(O) (substituted or unsubstituted alkyl), —NR c C(O)(substituted or unsubstituted alkenyl), —C(O)NR(substituted or unsubstituted alkyl), —C(O)NR c (substituted or unsubstituted alkenyl), —NO 2 , —S(═O)R c , —SR c , C(O) 2 R c , or —C(O)R c ; and

two adjacent R 1 's, taken together, form a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and

each R 2 is independently H or substituted or unsubstituted alkyl.

7 . The method of claim 6 , wherein the compound is:

8 . The method of claim 5 , wherein said compound corresponds to Formula (V):

9 . The method of claim 8 , wherein said compound is selected from the group consisting of:

10 . The method of claim 4 , wherein said compound corresponds to Formula (VI):

wherein Z 1 is O or S; and Z 2 is CR 3 or N.

11 . The method of claim 10 , wherein said compound corresponds to Formula (VII):

wherein:

each R 1 is independently H, halogen, substituted or unsubstituted alkyl , —O(substituted or unsubstituted alkyl) , —O(substituted or unsubstituted alkenyl), —NR c C(O)O(substituted or unsubstituted alkyl), —NR c C(O) (substituted or unsubstituted alkyl), —NR c C(O)(substituted or unsubstituted alkenyl), —C(O)NR c (substituted or unsubstituted alkyl), —C(O)NR c (substituted or unsubstituted alkenyl), —NO 2 , —S(═O)R c , —SR c , C(O) 2 R c , or —C(O)R c ; and

each R 2 is independently H or substituted or unsubstituted alkyl.

12 . The method of claim 10 , wherein said compound corresponds to Formula (VIII):

13 . The method of claim 12 , wherein said compound is selected from the group consisting of:

14 . The method of claim 5 , wherein said compound corresponds to Formula (IX):

wherein:

L is a linker selected from the group consisting of a covalent bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkylene, —C(O)NH—, —C(O)—, —NH—, —O—, —S—, —O(substituted or unsubstituted alkylene)-, —N(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkenylene)-, —NHC(O)(substituted or unsubstituted alkylene)-, —NHC(O)(substituted or unsubstituted alkenylene)-, —C(O)(substituted or unsubstituted alkenylene)-, and —NHC(O)(substituted or unsubstituted alkylene)S(substituted or unsubstituted alkylene)C(O)NH—; and

T is a mono-, bi-, or tricyclic, substituted or unsubstituted cycloalkyl, heterocyclyl, aryl, or heteroaryl.

15 . The method of claim 14 , wherein T of said compound corresponds to Formula (X):

wherein A is a substituted or unsubstituted five or six-membered heterocyclyl, aryl, or heteroaryl; and B is a substituted or unsubstituted five or six-membered heterocyclene, arylene, or heteroarylene, wherein A and B together form a fused two ring moiety.

16 . The method of claim 15 , wherein said compound corresponds to Formula (XI):

17 . The method of claim 16 , wherein L of said compound is a covalent bond, —C(O)NH(substituted or unsubstituted alkylene), —O(substituted or unsubstituted alkylene)-, —C(O)NH—, or —NHC(O)(alkylene)-.

18 . The method of claim 17 , wherein B of said compound is a substituted or unsubstituted five-membered heteroarylene.

19 . The method of claim 18 , wherein said compound is selected from the group consisting of:

20 . The method of claim 17 , wherein B of said compound is a substituted or unsubstituted 6-membered arylene or heteroarylene.

21 . The method of claim 20 , wherein said compound is selected from the group consisting of:

22 . The method of claim 20 , wherein said compound is selected from the group consisting of:

23 . The method of claim 14 , wherein T of said compound is a tricyclic, substituted or unsubstituted aryl, heterocyclyl, or heteroaryl.

24 . The method of claim 23 , wherein said compound is selected from the group consisting of:

25 . The method of claim 5 , wherein said compound corresponds to Formula (XII):

wherein:

L is a linker selected from the group consisting of a covalent bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkylene, —C(O)NH—, —C(O)—, —NH—, —O—, —S—, —O(substituted or unsubstituted alkylene)-, —N(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkenylene)-, —NHC(O)(substituted or unsubstituted alkylene)-, —NHC(O)(substituted or unsubstituted alkenylene)-, —C(O)(substituted or unsubstituted alkenylene)-, and —NHC(O)(substituted or unsubstituted alkylene)S(substituted or unsubstituted alkylene)C(O)NH—; and

each of X 1 -X 5 is independently C, CR, N, NR, S, or O, wherein no more than three of X 1 -X 5 is a heteroatom, and no two adjacent ring atoms are O or S; where

each R is independently H, halogen, substituted or unsubstituted alkyl, —OH, substituted or unsubstituted alkoxy, —OC(O)R d , —NO 2 , —N(R d ) 2 , —SR d , —S(O) j R d where j is 1 or 2, —NR d C(O)R d , —C(O) 2 R d , —C(O)N(R d ) 2 or —C(O)R d , or two adjacent R's are taken together to form a substituted or unsubstituted aryl or hetroaryl, where

each R d is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

26 . The method of claim 25 , wherein said compound corresponds to Formula (XIII):

27 . The method of claim 26 , wherein L of said compound is a covalent bond, —C(O)NH—, or —O(substituted or unsubstituted alkylene)-.

28 . The method of claim 27 , wherein

of said compound is selected from the group consisting of:

29 . The method of claim 28 , wherein said compound is selected from the group consisting of:

30 . The method of claim 5 , wherein said compound corresponds to Formula (XIV):

L is a linker selected from the group consisting of a covalent bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkylene, —C(O)NH—, —C(O)—, —NH—, —O—, —S—, —O(substituted or unsubstituted alkylene)-, —N(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkenylene)-, —NHC(O)(substituted or unsubstituted alkylene)-, —NHC(O)(substituted or unsubstituted alkenylene)-, —C(O)(substituted or unsubstituted alkenylene)-, and —NHC(O)(substituted or unsubstituted alkylene)S(substituted or unsubstituted alkylene)C(O)NH—; and

each of X 1 -X 5 is independently C, CR, N, NR, S, or O, wherein no more than three of X 1 -X 5 is a heteroatom, and no two adjacent ring atoms are O or S; where

each R is independently H, halogen, substituted or unsubstituted alkyl, —OH, substituted or unsubstituted alkoxy, —OC(O)R d , —NO 2 , —N(R d ) 2 , —SR d , —S(O) j R d where j is 1 or 2, —NR d C(O)R d , —C(O) 2 R d , —C(O)N(R d ) 2 or —C(O)R d , or two adjacent R's are taken together to form a substituted or unsubstituted aryl or hetroaryl, where

each R d is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

31 . The method of claim 30 , wherein said compound corresponds to Formula (XV):

32 . The method of claim 31 , wherein said compound is selected from the group consisting of:

33 . The method of claim 31 , wherein said compound corresponds to Formula (XVI):

34 . The method of claim 33 , wherein said compound is selected from the group consisting of:

35 . The method of claim 31 , wherein said compound corresponds to Formula (XVII):

36 . The method of claim 35 , wherein said compound is selected from the group consisting of:

37 . The method of claim 31 , wherein said compound corresponds to Formula (XVIII):

38 . The method of claim 37 , wherein said compound is selected from the group consisting of:

39 . The method of claim 31 , wherein said compound corresponds to Formula (XIX):

40 . The method of claim 39 , wherein said compound is selected from the group consisting of:

41 . The method of claim 31 , wherein said compound corresponds to Formula (XX):

42 . The method of claim 41 , wherein said compound is selected from the group consisting of:

43 . The method of claim 31 , wherein said compound corresponds to Formula (XXI):

44 . The method of claim 43 , wherein L of said compound is —NHC(O)—, —NHC(O)(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkylene), —C(O)NH(substituted or unsubstituted alkenylene), or —NHC(O)(substituted or unsubstituted alkenylene)-.

45 . The method of claim 44 , wherein said compound is selected from the group consisting of:

46 . The method of claim 43 , wherein L of said compound is —O— or —O(substituted or unsubstituted alkylene)-.

47 . The method of claim 46 , wherein said compound is selected from the group consisting of:

48 . The method of claim 43 , wherein L of said compound is -(substituted or unsubstituted alkylene)- or —NHC(O)(alkylene)S(alkylene)C(O)NH—.

49 . The method of claim 48 , wherein said compound is selected from the group consisting of:

50 . The method of claim 14 , wherein said compound corresponds to Formula (XXII):

wherein:

L 1 is a linker selected from the group consisting of a covalent bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkylene, —C(O)NH—, —C(O)—, —NH—, —O—, —S—, —O(substituted or unsubstituted alkylene)-, —N(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkylene)-, —C(O)NH(substituted or unsubstituted alkenylene)-, —NHC(O)(substituted or unsubstituted alkylene)-, —NHC(O)(substituted or unsubstituted alkenylene)-, —C(O)(substituted or unsubstituted alkenylene)-, and —NHC(O)(substituted or unsubstituted alkylene)S(substituted or unsubstituted alkylene)C(O)NH—;

U is a substituted or unsubstituted cycloalkyl, hetrocycloalkyl, aryl, or heteroaryl; and

V is a substituted or unsubstituted cycloalkylene, heterocyclene, arylene, or heteroarylene;

51 . The method of claim 50 , wherein said compound corresponds to Formula (XXIII):

52 . The method of claim 51 , wherein L 1 of said compound is a bond, —O(substituted or unsubstituted alkylene)-, -(substituted or unsubstituted alkylene)-, or —S—; and L of said compound is a covalent bond, —C(O)NH—, —C(O)NH(substituted or unsubstituted alkylene), or —NHC(O)(substituted or unsubstituted alkylene)-.

53 . The method of claim 52 , wherein V of said compound is substituted or unsubstituted 5-membered heteroarylene.

54 . The method of claim 53 , wherein said compound is selected from the group consisting of:

55 . The method of claim 51 , wherein said compound corresponds to Formula (XXIV):

wherein:

each of X 1 -X 4 is independently C, CR, or N, wherein no more than two of X 1 -X 5 is N; where

each R is independently H, halogen, substituted or unsubstituted alkyl, —OH, substituted or unsubstituted alkoxy, —OC(O)R d , —NO 2 , —N(R d ) 2 , —SR d , —S(O) j R d where j is 1 or 2, —NR d C(O)R d , —C(O) 2 R d , —C(O)N(R d ) 2 or —C(O)R d , or two adjacent R's are taken together to form a substituted or unsubstituted aryl or hetroaryl, where

each R d is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

56 . The method of claim 55 , wherein U of said compound is substituted or unsubstituted pyrimidinyl or pyridinyl.

57 . The method of claim 56 , wherein said compound is selected from the group consisting of:

58 . The method of claim 55 , wherein U of said compound is substituted or unsubstituted phenyl.

59 . The method of claim 58 , wherein said compound is selected from the group consisting of:

60 . The method of claim 51 , wherein said compound is selected from the group consisting of:

61 . The method of claim 14 , wherein said compound corresponds to Formula (XXV):

wherein T is substituted or unsubstituted cycloalkyl or heterocylyl.

62 . The method of claim 61 , wherein said compound is selected from the group consisting of:

63 . The method of claim 1 , wherein said compound is

64 . The method of claim 1 , wherein said compound is selected from the group consisting of:

65 . A method of treating a c-kit mediated disease, said method comprising administering a therapeutically effective amount of a compound corresponding to Formula (IA):

wherein:

M is substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl;

N is a substituted or unsubstituted aryl, or substituted or unsubstituted hetroaryl; and

K is

Y is O or S;

each R k is independently H, halogen, substituted or unsubstituted alkyl, —OH, substituted or unsubstituted alkoxy, —OC(O)R 2 , —NO 2 , —N(R 2 ) 2 , —SR 2 , —C(O)R 2 , —C(O) 2 R 2 , —C(O)N(R 2 ) 2 , or —N(R 2 )C(O)R 2 ,

each R 2 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or wherein two R 2 groups are linked together by an optionally substituted alkylene; and

each n is independently 0, 1, 2, 3 or 4;

or an active metabolite, or a pharmaceutically acceptable prodrug, isomer, pharmaceutically acceptable salt or solvate thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 7, 2008
From: HORIZON TECHNOLOGY FUNDING COMPANY LLC
To: AMBIT BIOSCIENCES CORPORATION
Reel/Frame 020619/0693 →
SECURITY AGREEMENT Recorded Oct 17, 2005
From: AMBIT BIOSCIENCES CORPORATION
To: HORIZON TECHNOLOGY FUNDING COMPANY LLC
Reel/Frame 017261/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2004
From: MILANOV, ZDRAVKO V.; PATEL, HITESH K.; GROTZFELD, ROBERT M.; MEHTA, SHAMAL A.; LAI, ANDILIY G.; LOCKHART, DAVID J.
To: AMBIT BIOSCIENCES CORPORATION
Reel/Frame 016006/0193 →